[{"orgOrder":0,"company":"Ever Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ever Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ever Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ever Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Natco Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Natco Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Centre Oscar Lambret","sponsor":"French Sarcoma Group | Study Group of Bone Tumors","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Centre Oscar Lambret","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Oscar Lambret \/ French Sarcoma Group | Study Group of Bone Tumors","highestDevelopmentStatusID":"8","companyTruncated":"Centre Oscar Lambret \/ French Sarcoma Group | Study Group of Bone Tumors"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Bergoni\u00e9 \/ PharmaMar","highestDevelopmentStatusID":"7","companyTruncated":"Institut Bergoni\u00e9 \/ PharmaMar"},{"orgOrder":0,"company":"Institut Bergoni\u00e9","sponsor":"AstraZeneca | PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Institut Bergoni\u00e9","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institut Bergoni\u00e9 \/ AstraZeneca | PharmaMar","highestDevelopmentStatusID":"6","companyTruncated":"Institut Bergoni\u00e9 \/ AstraZeneca | PharmaMar"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"PharmaMar | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Italian Sarcoma Group \/ PharmaMar | AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Italian Sarcoma Group \/ PharmaMar | AstraZeneca"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"PharmaMar | AstraZeneca | Istituto Mario Negri","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Italian Sarcoma Group \/ PharmaMar | AstraZeneca | Istituto Mario Negri","highestDevelopmentStatusID":"8","companyTruncated":"Italian Sarcoma Group \/ PharmaMar | AstraZeneca | Istituto Mario Negri"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"Istituto Mario Negri","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Italian Sarcoma Group \/ Istituto Mario Negri","highestDevelopmentStatusID":"8","companyTruncated":"Italian Sarcoma Group \/ Istituto Mario Negri"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Italian Sarcoma Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Italian Sarcoma Group \/ Undisclosed"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Italian Sarcoma Group \/ PharmaMar","highestDevelopmentStatusID":"8","companyTruncated":"Italian Sarcoma Group \/ PharmaMar"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Italian Sarcoma Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Italian Sarcoma Group \/ Undisclosed"},{"orgOrder":0,"company":"Mario Negri Institute for Pharmacological Research","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Mario Negri Institute for Pharmacological Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mario Negri Institute for Pharmacological Research \/ PharmaMar","highestDevelopmentStatusID":"8","companyTruncated":"Mario Negri Institute for Pharmacological Research \/ PharmaMar"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Italian Sarcoma Group \/ PharmaMar","highestDevelopmentStatusID":"10","companyTruncated":"Italian Sarcoma Group \/ PharmaMar"},{"orgOrder":0,"company":"Mario Negri Institute for Pharmacological Research","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Mario Negri Institute for Pharmacological Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mario Negri Institute for Pharmacological Research \/ PharmaMar","highestDevelopmentStatusID":"8","companyTruncated":"Mario Negri Institute for Pharmacological Research \/ PharmaMar"},{"orgOrder":0,"company":"Italian Sarcoma Group","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Italian Sarcoma Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Italian Sarcoma Group \/ PharmaMar","highestDevelopmentStatusID":"10","companyTruncated":"Italian Sarcoma Group \/ PharmaMar"},{"orgOrder":0,"company":"Grupo Espanol de Investigacion en Sarcomas","sponsor":"Centre L\u00e9on B\u00e9rard | Italian Sarcoma Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Grupo Espanol de Investigacion en Sarcomas","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grupo Espanol de Investigacion en Sarcomas \/ Centre L\u00e9on B\u00e9rard | Italian Sarcoma Group","highestDevelopmentStatusID":"7","companyTruncated":"Grupo Espanol de Investigacion en Sarcomas \/ Centre L\u00e9on B\u00e9rard | Italian Sarcoma Group"},{"orgOrder":0,"company":"North Eastern German Society of Gynaecological Oncology","sponsor":"IKF Nordwest | PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase IV","graph3":"North Eastern German Society of Gynaecological Oncology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North Eastern German Society of Gynaecological Oncology \/ IKF Nordwest | PharmaMar","highestDevelopmentStatusID":"11","companyTruncated":"North Eastern German Society of Gynaecological Oncology \/ IKF Nordwest | PharmaMar"},{"orgOrder":0,"company":"University Medicine Greifswald","sponsor":"IKF Nordwest | PharmaMar | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"University Medicine Greifswald","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medicine Greifswald \/ IKF Nordwest | PharmaMar | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"University Medicine Greifswald \/ IKF Nordwest | PharmaMar | Bristol Myers Squibb"},{"orgOrder":0,"company":"Universit\u00e4t M\u00fcnster","sponsor":"Anturec Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Universit\u00e4t M\u00fcnster","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Universit\u00e4t M\u00fcnster \/ Anturec Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Universit\u00e4t M\u00fcnster \/ Anturec Pharmaceuticals"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"TOYO Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ TOYO Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ TOYO Pharmaceutical"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Adium Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Adium Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Adium Pharma"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"PharmaMar","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaMar \/ STADA Arzneimittel","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ STADA Arzneimittel"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Onko Kocsel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Onko Kocsel Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Onko Kocsel Pharmaceuticals"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Key Oncologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Key Oncologics","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Key Oncologics"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Trabectedin","moa":"||DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"PharmaMar","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaMar \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PharmaMar \/ Undisclosed"},{"orgOrder":0,"company":"Sarcoma Oncology Research Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sarcoma Oncology Research Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcoma Oncology Research Center \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Sarcoma Oncology Research Center \/ Undisclosed"},{"orgOrder":0,"company":"University of Miami","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Miami \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"University of Miami \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Sarcoma Alliance for Research through Collaboration","sponsor":"Johnson & Johnson Innovative Medicine | National Institutes of Health | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sarcoma Alliance for Research through Collaboration","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcoma Alliance for Research through Collaboration \/ Johnson & Johnson Innovative Medicine | National Institutes of Health | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sarcoma Alliance for Research through Collaboration \/ Johnson & Johnson Innovative Medicine | National Institutes of Health | National Cancer Institute"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ PharmaMar","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ PharmaMar"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ PharmaMar","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ PharmaMar"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ PharmaMar","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ PharmaMar"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ PharmaMar","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ PharmaMar"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Undisclosed","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Johnson & Johnson","highestDevelopmentStatusID":"1","companyTruncated":"UT Southwestern Medical Center \/ Johnson & Johnson"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Specialised Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Specialised Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Specialised Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"European Organisation for Research and Treatment of Cancer","sponsor":"PharmaMar","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"European Organisation for Research and Treatment of Cancer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Catheter","sponsorNew":"European Organisation for Research and Treatment of Cancer \/ PharmaMar","highestDevelopmentStatusID":"10","companyTruncated":"European Organisation for Research and Treatment of Cancer \/ PharmaMar"},{"orgOrder":0,"company":"Sonnet BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"SON-1010","moa":"||IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sonnet BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sonnet BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sonnet BioTherapeutics \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for (1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-Trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro(6,16-(epithiopropanooxymethano)-7,13-imino-6aH-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocine-20,1'(2&
Details :
EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.
Details :
SON-1010 (IL12-FHAB) is a immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Details :
Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Details :
Yondelis (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, that acts a DNA inhibitor. It is indicated for the treatment of of patients with unresectable or metastatic liposarcoma or leiomyo...
Details :
Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell d...
Details :
Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Details :
Trabectedin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Sarcoma.
Details :
Yondelis-Generic (trabectedin) is a DNA inhibitor, small molecule drug candidate. It is being developed for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Details :
The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-con...
Details :
PharmaMar has granted to STADA a license to market the Yondelis® (trabectedin) marine-derived cancer treatment in 15 Middle East-North Africa countries. Yondelis® is marketed in several MENA countries for the treatment of soft tissue sarcoma and relaps...
Reset All
Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.
